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Approaches for peptide and protein cyclisation
Heather C. Hayes,a Louis Y. P. Luk *a,b and Yu-Hsuan Tsai *a,c
The cyclisation of polypeptides can play a crucial role in exerting biological functions, maintaining stability
under harsh conditions and conferring proteolytic resistance, as demonstrated both in nature and in the
laboratory. To date, various approaches have been reported for polypeptide cyclisation. These approaches
range from the direct linkage of N- and C- termini to the connection of amino acid side chains, which
can be applied both in reaction vessels and in living systems. In this review, we categorise the cyclisation
approaches into chemical methods (e.g. direct backbone cyclisation, native chemical ligation, aldehyde-
based ligations, bioorthogonal reactions, disulphide formation), enzymatic methods (e.g. subtiligase var-
iants, sortases, asparaginyl endopeptidases, transglutaminases, non-ribosomal peptide synthetases) and
protein tags (e.g. inteins, engineered protein domains for isopeptide bond formation). The features of
each approach and the considerations for selecting an appropriate method of cyclisation are discussed.
1. Introduction
Polypeptides are important biological molecules for all living
systems. Most peptides and proteins are linear polymers com-
posed of the 20 canonical amino acids connected through
amide bonds. Loosely speaking, peptides are defined as linear
chains of ≤50 amino acid residues and proteins of >50
residues.
In the human body and in many other animals, peptides
are used as hormones for signal transduction (e.g. insulin),
whereas proteins are indispensable for cellular structure and
function. Indeed, peptides and proteins are closely associated
with nearly all human diseases, and thus they have been uti-
lised for disease prevention or treatment.1–4 In particular, pep-
tides have become increasingly popular as therapeutics due to
their high specificity, high activity and low toxicity.5 On a
different note, proteins that catalyse reactions have been exten-
sively employed in both research and industrial applications.6
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These biocatalysts are attractive alternatives to traditional
chemical catalysts owing, in particular, to their substrate speci-
ficity, catalytic efficiency and biocompatibility. Towards enhan-
cing the biophysical properties of peptides and proteins, as
well as expanding their scope of application as therapeutics
and catalysts, cyclisation of peptides and proteins has become
a burgeoning field of research.
In nature, many polypeptides are found to be cyclised, a
feature that is often intrinsically associated with their biologi-
cal function. Cyclisation can be categorised into four general
classes: side chain-to-side chain, head-to-tail (also known as
backbone cyclisation), head-to-side chain and side chain-to-
tail (Fig. 1). Side chain-to-side chain cyclisation occurs when a
bond is formed between the side chain functionalities of two
amino acid residues (Fig. 1a). One prominent example is intra-
molecular disulphide bond formation between the thiol func-
tionalities of two cysteine residues, leading to a type of cyclic
structure, commonly found in peptides and proteins such as
insulin and antibodies. It is estimated that about 50% of
cysteine residues in polypeptides are found in the form of dis-
ulphide bonds.7 Other types of side chain cyclisation, includ-
ing non-native linkages, are also possible and will be discussed
throughout this review. Head-to-tail terminus cyclisation is
another commonly observed form of cyclisation. As the first
residue in a chain of amino acids has an amino functionality
(i.e. N-terminus), and the last residue has a carboxylate func-
tionality (i.e. C-terminus), polypeptides are typically direc-
tional. Subsequently, cyclisation can be achieved by joining
the N- and C-termini through an amide bond (Fig. 1b). Head-
to-tail peptide cyclisation has been observed in microorgan-
isms and plants, such as kalata B1 from the plant Oldenlandia
affinis and bacteriocin AS-48 produced by the bacterium
Enterococcus faecalis.8,9 Furthermore, a recent report shows
that head-to-tail cyclic peptides are prevalent in normal flora
such as those in the human gut.10 Meanwhile, the formation
of a lactam, lactone or thiolactone between either terminus
with an appropriate side chain functional group (Fig. 1c and
d) results in side chain-to-terminus cyclisation. For example,
bacitracin is an antibiotic side chain-to-tail cyclic peptide pro-
duced by Bacillus subtilis, in which a bond is formed between
a lysine side chain and the C-terminus.11
As potential drugs, both natural and synthetic peptides are
increasingly researched due to their favourable character-
istics.12 However, they often suffer from low oral bioavailability
and metabolic instability. These shortcomings can often be
addressed by cyclisation. Firstly, peptide cyclisation can lead
to improved biological activity by enabling enhanced binding
towards the target molecule. As a result of decreased confor-
mational flexibility, the more rigid macrocycle has a reduced
change in entropy upon binding to the target molecule com-
pared to that of the linear peptide.13,14 Secondly, head-to-tail
cyclic peptides have increased resistance to hydrolysis by exo-
peptidases due to the absence of the free termini. Thirdly,
membrane permeability and cytoplasmic delivery of the mole-
cule is enhanced, though the exact mechanism remains not
entirely clear.15 Consequently, the favourable pharmacological
properties possessed by cyclic peptides makes them attractive
therapeutic candidates. Indeed, nine cyclic peptide drugs were
approved for market between 2006 and 2015.12 While the
majority of cyclic peptides in clinical use are currently derived
from natural sources, the design of synthetic cyclic peptide
drug candidates is becoming increasingly common, aided by
advances in computational design and high-throughput
screening.16
For proteins, cyclisation can be employed to improve stabi-
lity so that enzymes can function outside of their native con-
ditions, such as at elevated temperatures, in acidic or basic
environments and in the presence of organic solvents or
additives.15,17,18 According to polymer theory, the overall
increase in the stability of a cyclised protein originates from
the destabilisation of the unfolded state.19 Upon cyclisation,
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Fig. 1 Schematic illustration of cyclisation modes: (a) side chain-to-
side chain, (b) head-to-tail, also known as backbone cyclisation, (c) tail-
to-side chain, and (d) head-to-side chain.
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the number of conformational states accessible to the
unfolded polypeptide is reduced. As a result, the entropy of the
unfolded state is decreased and, consequently, the Gibbs free
energy is increased. It should be noted that an offsetting
enthalpic cost may occur if cyclisation introduces strain to the
system, in which case, the desired stabilisation may not be
achieved.20 Although the stabilisation of industrially relevant
enzymes usually relies on techniques such as directed evol-
ution and computational design,21 a number of proteins have
been shown to benefit from cyclisation. These include
β-lactamase, dihydrofolate reductase and luciferase, all of
which exhibit improved activity at elevated temperatures com-
pared to their linear forms.22–24
In this review, we first introduce different approaches for
peptide and protein cyclisation. Broadly speaking, these
approaches can be categorised as either chemical, enzymatic
or protein tag methods. While each approach has its own
strengths and limitations, the choice of the most appropriate
approach largely depends on factors such as the desired appli-
cation and means to produce the material. Additional con-
siderations will be discussed in the latter part of the review.
2. Chemical methods for cyclisation
Many chemical ligation methods have been developed over the
years, which when applied in an intramolecular manner to the
peptide or protein of interest, result in cyclisation. The reader
should note that in this review the term ligation refers to bond
formation between two polypeptide functional groups,
whether this is in an inter- or intramolecular manner.
Meanwhile, the term cyclisation specifically refers to intra-
molecular ligation resulting in one of the four classes of cyclic
polypeptide products discussed in section 1 (Fig. 1). In this
section, we briefly discuss the strengths and limitations of
some important traditional chemical cyclisation methods. We
then highlight recent examples that have built on these
methods and address some of their shortcomings. It should
be noted that examples discussed here are in no way exhaus-
tive, and we direct readers interested in this area to more com-
prehensive reviews of this subject.25–28
2.1. Direct amide bond formation
Amide bond formation between carboxylic acid and amine
groups can take place via direct condensation using high
temperatures or microwave irradiation.29,30 However, such
harsh conditions are incompatible with most peptides and
proteins. Thus, reactions with milder conditions have been
developed for polypeptide ligation. This is commonly achieved
by transforming the C-terminal –OH into a better leaving
group, such as an acyl halide, acyl azide, anhydride or an acti-
vated ester, through the use of coupling reagents.31
Accordingly, nucleophilic (e.g. Lys, Ser, Thr) and carboxylate
(e.g. Asp, Glu) amino acid side chains must be protected to
prevent side reactions, and thus this approach is more suitable
for peptides that are synthesised in a fully protected form. In
addition, additives are often used in combination with coup-
ling reagents to suppress racemisation at the ligation site and
enhance the rate of reaction.32 For example, in the total syn-
thesis of a 13 residue depsicyclic peptide antibiotic, texiobac-
tin, the cyclisation step was successfully carried out using a
combination of coupling reagents (HOAt/OxymaPure/HATU)
with a tertiary amine base DIEA.33 However, alternative cyclisa-
tion methods that do not require protecting strategies and that
can be carried out under physiological conditions are often
preferred.
2.2. Native chemical ligation
Native chemical ligation (NCL) is as an effective method for
linking two unprotected peptide fragments (Fig. 2a).34,35 One
fragment contains a C-terminal thioester, and the other con-
tains an N-terminal cysteine residue. Both fragments can be
produced either chemically by solid-phase peptide synthesis or
recombinantly from cells (see section 4.1 for the recombinant
introduction of C-terminal thioesters). Importantly, the reac-
tion proceeds in aqueous conditions at neutral pH, and toler-
ates the presence of chaotropic reagents (e.g. guanidine hydro-
chloride) as well as reducing agents. Mechanistically, the reac-
tion begins with the nucleophilic attack of the thiol group of
the N-terminal cysteine to the carbonyl carbon of the thioester
group, leading to rapid and reversible transthioesterification.
Subsequently, an S-to-N acyl shift generates the desired
peptide bond. This reaction is regio- and chemoselective, as
neither the presence of internal cysteine residues nor other
nucleophilic amino acid side chains interfere with the
reaction.
Fig. 2 Selected chemical ligation methods. (a) Peptide bond formation
by native chemical ligation. (b) Bond formation between a N-terminal
Ser/Thr/Cys and a C-terminal glycolaldehyde. (c) Ser/Thr ligation with a
C-terminal salicylaldehyde.
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Backbone cyclisation can be achieved by intramolecular
NCL. This was first demonstrated by Zhang and Tam with pep-
tides ranging from 5 to 16 residues. They observed a high yield
of cyclic product with no oligomer formation from inter-
molecular reaction, even at millimolar concentrations.36 More
recently, a series of cyclic peptides between 10 and 28 amino
acid residues, were prepared using a microfluidic NCL pro-
cedure.37 This enabled acceleration of the NCL reaction, with
fast ligation observed even with less reactive C-terminal thioe-
sters, such as those on Val, Ile or Pro. The microfluidic NCL
strategy was also successfully employed for the preparation of
an 18-residue cyclic peptide RTD-1, which displayed antibac-
terial activity against E. coli and S. aureus.
Over the years, a variety of other extensions to the NCL
methodology have been devised, expanding the scope of appli-
cation.35 For example, post-ligation desulphurisation using a
free-radical and metal-free reduction method can convert
cysteine into alanine.38 The removal of the cysteine and re-
placement by a much more abundant amino acid is advan-
tageous, as the desired polypeptide of interest can be gener-
ated with no trace of ligation or mutation. The development of
other thiol-containing unnatural amino acids has further
increased the number of sites possible for the ligation reaction
to take place.39 Another important extension to the NCL
method includes the use of selenium in place of sulphur to
accelerate the rate of the ligation reaction and minimise side
reactions such as thioester hydrolysis.34,35,40
2.3. Ligations relying on a C-terminal aldehyde
Serine and threonine residues can also be employed for ligat-
ing unprotected peptide fragments, and hence cyclisation. For
example, a C-terminal glycolaldehyde ester reacts chemoselec-
tively with an N-terminal serine or threonine (or cysteine)
residue to form an oxazolidine intermediate, which after
rearrangement generates a peptide bond in the form of pseu-
doproline structure (Fig. 2b).41 However, the reaction is slow
and leaves an unnatural functionality at the ligation site. To
overcome these limitations, a modified approach using a
C-terminal salicylaldehyde was developed.42 After oxazolidine
formation from the chemoselective reaction of the salicylalde-
hyde with the N-terminal Ser/Thr, an N,O-benzylidene acetal
amide intermediate is generated upon O–N acyl shift. Using
TFA the acyl group can then be removed, leaving a native
peptide bond at the ligation site (Fig. 2c). This Ser/Thr ligation
approach has been successfully applied to the synthesis of a
number of cyclic peptide natural products, including daptomy-
sin,43 cyclomontanin B,44 mahafacyclin B,45 among others.46,47
A C-terminal aldehyde functionality is also employed in a
recently developed cyclisation, known as CyClick (Fig. 3).48
Cyclisation proceeds with the reaction of the C-terminal alde-
hyde and the N-terminal amine, forming a cyclic peptide with
an imine intermediate. The imine group is subsequently
attacked by the adjacent amide nitrogen atom to form an imi-
dazolidinone. The final bicyclic product is thermodynamically
stable, driving the reaction toward intramolecular cyclisation.
This reaction could be performed at concentrations up to
100 mM without significant production of dimer or oligomer
side products from intermolecular reactions. It is noteworthy
that the ε-amine of lysine does not interfere with CyClick.
Though being efficient, highly chemoselective and stereo-
selective, CyClick has only been applied to synthetic peptides
due to the need for a C-terminal aldehyde functionality.
2.4. Bioorthogonal reactions
A bioorthogonal reaction involves two complementary
bioorthogonal functionalities, which do not react with natu-
rally occurring biological molecules, but selectively with each
other under physiological conditions.49 Thus, the use of
bioorthogonal reactions for peptide and protein modification
eliminates concerns about side reactions and off-target effects.
Theoretically, any bioorthogonal reaction can be used for
peptide and protein cyclisation, although site-specific introduc-
tion of the required bioorthogonal functionalities is the prerequi-
site. For instance, Staudinger ligation is based on the reduction of
an azide into an amine by a phosphine. For traceless backbone
cyclisation, a bifunctional phosphinothiol reagent was developed
(Fig. 4a).50 The ligation begins with a transthioesterification reac-
tion between the peptide thioester and phosphinothiol, followed
by reaction with the other peptide fragment bearing an
N-terminal azide. The resulting iminophosphorane intermediate
is then transformed into an amidophosphonium salt through a
cyclic tetrahedral intermediate. Hydrolysis of the amidophospho-
nium salt produces a native amide bond between the peptide frag-
ments. While the reaction has been successfully applied for cyclis-
ing synthetic peptides,51 the application of the Staudinger ligation
in aqueous solutions is limited due to the laborious preparation
of water-soluble phosphinothiols.52 The widespread application of
the Staudinger ligation has further been hindered by the require-
ment for substrates with glycine residues at the ligation site. Due
to increased steric strain on the tetrahedral intermediate in the
presence of bulkier residues, a covalent bond between the oxygen
and the oxophilic phosphorous atom is favoured over thiol displa-
cement. However, by increasing the electron density on the phos-
phorous atom of the phosphinothiol reagent, P–O bond for-
mation is discouraged and an improved yield can be achieved for
non-glycyl Staudinger ligation reactions.53
In a second example, an amide bond can be formed by
α-ketoacid-hydroxylamine (KAHA) ligation.54 This chemo-
selective ligation takes place between an N-terminal hydroxyl-
amine and a C-terminal α-ketoacid. Depending on the nature
of the hydroxylamine substituent, there are two main mecha-
Fig. 3 Peptide cyclisation by CyClick involving the N-terminal amine
and the C-terminal aldehyde (5 ≤ n ≤ 9, m = n − 4).
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nisms. Type I KAHA ligation uses a free hydroxylamine, while
type II KAHA involves the use of an O-substituted hydroxylamine.
Though demonstrated to be a feasible method for the cyclisation
of medium length peptides, type I KAHA is rarely used, mainly
due to the instability of the free hydroxylamine in aqueous
media.55 For the type II KAHA ligation, a water stable
O-substituted hydroxylamine, most commonly 5-oxaproline, can
be easily prepared and incorporated using solid-phase peptide
synthesis. After cleavage from the resin, the α-ketoacid and 5-oxa-
proline cyclise directly, generating a depsipeptide intermediate,
which under basic conditions, undergoes O–N acyl shift to give
the desired cyclic product, ligated by an amide bond (Fig. 4b).56
A homoserine residue is formed at the ligation site, however, by
replacement of the N-terminal oxaproline with an oxazetidine
functionality, a serine residue is instead produced upon KAHA
ligation.57 Type II KAHA ligation has been used to cyclise a
variety of short peptides.58 Furthermore, this approach was
shown to be compatible with larger and more challenging sub-
strates, as demonstrated by the chemical synthesis of the cyclic
antibacterial protein AS-28, which has 70 amino acid residues.59
Recently, we reported a novel bioorthogonal reaction invol-
ving 1,2-aminothiol and 2-((alkylthio)(aryl)methylene)malono-
nitrile (TAMM) (Fig. 4c).60 The TAMM functionality is stable
over a range of pH values and temperatures. Though an un-
natural moiety remains in the product, this reaction is fast (k
∼10 M−1 s−1) and specific with no cross reaction with internal
cysteine or other nucleophilic residues observed. Using this
reaction, cyclisation of proteins on bacteriophages was demon-
strated with no reduction in phage infectivity observed.
The bioorthogonal reactions mentioned thus far all require
non-native functionalities, which can be readily introduced
using solid-phase peptide synthesis or in some instances by
recombinant approaches.49,61 For example, the technique of
genetic code expansion enables site-specific incorporation of
unnatural (non-canonical) amino acids that contain a
bioorthogonal functionality.62,63 To do this, a blank codon
(usually the amber stop codon, UAG) and an orthogonal ami-
noacyl-tRNA synthetase/tRNA pair are required. The orthog-
onal synthetase does not recognise any endogenous tRNA or
canonical amino acids as its substrate, and the orthogonal
tRNA is not a substrate of any endogenous synthetases. The
orthogonal synthetase specifically loads the orthogonal tRNA
with the designated unnatural amino acid. This aminoacylated
tRNA recognises the blank codon on the mRNA and directs the
site-specific incorporation of the unnatural amino acid into
the target protein.62,63
Chin and co-workers have demonstrated the use of copper-
catalysed azide–alkyne cycloaddition (CuAAC) (Fig. 4d) for
protein cyclisation through genetically incorporated azide- and
alkyne-containing amino acids.64 By definition, “click”-type
reactions, such as CuAAC, are simple, rapid, high yielding,
stereospecific and wide in scope.65 As such, CuAAC has been
used extensively for peptide cyclisation,66 which can be carried
out under mild conditions in a variety of solvents, including
water.67,68 The 1,4-disubstituted triazole formed at the ligation
site, although not a natural functionality of polypeptides, is
known to effectively mimic the topology and electronic pro-
perties of native trans-amide bonds.69 Theoretically, CuAAC
can be employed for peptide and protein cyclisation in live
cells through the use of appropriate ligands that can increase
the reaction rate and reduce catalyst toxicity.70,71
In place of a terminal alkyne, a strained alkyne can react
with an azide in the absence of a catalyst under physiological
conditions.72 However, this strain promoted azide–alkyne
cycloaddition (SPAAC) lacks the regiospecificity of CuAAC, and
forms a mixture of 1,4-disubstituted products. Furthermore,
the synthesis of strained alkynes is more laborious.73
Nevertheless, a peptide cyclised using SPAAC exhibited
improved proteolytic stability and binding affinity compared to
its linear peptide counterpart.74
Alternatively, through the use of a ruthenium(II) catalyst, the
1,5-disubstituted regioisomer is generated upon azide–alkyne
cycloaddition (RuAAC).75,76 The 1,5-disubstituted triazole
mimics a cis-amide bond and is beneficial to cyclisation of pep-
tides not only as the cyclisation machinery, but also when intro-
duced into the peptide chain before cyclisation, it acts as a turn
inducer to bring the linear termini into close proximity for lig-
ation.77 In addition, ruthenium catalysts can also be used for
ring-closing metathesis, which was successfully utilised for the
stabilisation of α-helices through peptide stapling.78,79 For more
detailed discussions on metal-catalysed polypeptide cyclisation
we direct the interested readers to references.80–82
2.5. Disulphide bonds
Disulphide bond formation is arguably the most common
chemical method for cyclisation (Fig. 5a). About 30% of
eukaryotic proteins have at least one disulphide bond, which
Fig. 4 Selected bioorthogonal reactions for peptide/protein cyclisation:
(a) traceless Staudinger ligation, (b) type II KAHA ligation, (c) TAMM con-
densation, and (d) CuAAC.
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can stabilise the protein three-dimensional structure and regu-
late protein function.7 Cysteine residues can be easily intro-
duced into amino acid chains by either chemical or recombi-
nant means, and disulphide bonds usually form spontaneously
upon exposure to air. This concept has been used to engineer
proteins with a cyclic structure by introducing two cysteine resi-
dues.18 However, for proteins with several cysteine residues,
there are many possible disulphide bond patterns. For example,
a protein with 6 cysteine residues can form 3 intramolecular dis-
ulphide bonds in 15 (5 × 3 × 1) different ways. While cells
produce enzymes to ensure the formation of the correct disul-
phide bond pattern,83 the process can be difficult to control in
reaction vessels and often leads to a mixture of products.
Orthogonal cysteine protecting groups can be employed to
facilitate regioselective disulphide bond formation in cysteine-
rich peptides.84 Alternatively, to overcome the high number of
possible disulphide bond patterns, orthogonal disulphide
pairing has been developed. This concept relies on a unique
sequence of cysteine residues or unnatural side chain func-
tionalities to reduce the number of possible disulphide bond
patterns. For example, the two cysteine residues in a CXC
motif (X = any amino acid) do not form a disulphide bond
with each other. Instead, formation of two disulphide bonds
between two CXC motifs is preferred (Fig. 5b).85 Moreover, if
penicillamine (Pen) is present, formation of a mixed disul-
phide bond is thermodynamically preferred over disulphide
bond formation between two cysteine residues or two penicilla-
mine residues (Fig. 5c).86 However, no disulphide bond is
formed in Pen–X–C motifs, just like CXC motifs. By combining
these two orthogonal disulphide pairing strategies, it was
demonstrated that for a series of peptide sequences containing
six thiol functional groups, the number of isomers obtained
was as low as four, and in some cases, only one specific isomer
was isolated.87 Similarly, a selenocysteine residue or an un-
natural dithiol amino acid (Dtaa) can also be used to moderate
the number of possible disulphide patterns (Fig. 5d).88,89
While orthogonal disulphide pairing is effective in mini-
mising the number of isomers generated, their use is generally
limited to synthetic materials due to the requirement of un-
natural amino acids such as penicillamine. Furthermore, dis-
ulphide bonds are not stable under reductive environments
(e.g. cytosol) and can be disrupted by thiol-containing mole-
cules through a thiol-disulphide exchange reaction (Fig. 5e).90
Disulphide stapling reagents have addressed the stability
issue. A stapling reagent normally contains two electrophiles,
such as arsenous acid derivatives,91 dibromopyridazinediones,92
disubstituted maleimides,93,94 perfluoroaryl deriviatives,95
among others (Fig. 5f).96,97 These molecules can be subjected
to two nucleophilic additions or substitutions by two thiol
groups. Thus, after a disulphide bond is reduced, the addition
of a disulphide stapling reagent re-bridges the side chain of two
cysteine residues as more stable thioether linkages.
2.6. Remarks
In summary, the most common limitation for chemical cyclisa-
tion methods is the need for functionalities not provided by
the 20 canonical amino acids. Nevertheless, some approaches,
such as cyclisation by disulphide bond formation, do employ
canonical amino acids. In addition, advances in genetic code
expansion have enabled the site-specific incorporation of some
unnatural amino acids with the required functionalities. This
has allowed the recombinantly produced materials to be sub-
jected to chemical cyclisation approaches, as well as the appli-
cation of chemical approaches in living systems.
3. Enzymatic methods for cyclisation
Enzymes are known for their efficiency and selectivity in cata-
lysing reactions under mild conditions. In addition, an
enzyme can often catalyse both the forward and the reverse
Fig. 5 Cyclisation through disulphide bonds. (a) A disulphide bond is
formed and cleaved under oxidative and reductive conditions, respect-
ively. (b) Orthogonal disulphide pairing using the CXC motif (X = any
amino acid), which does not form a disulphide bond between two Cys
residues separated by one amino acid. (c) In the presence of penicilla-
mine (Pen) residues, Pen and Cys form thermodynamically more stable
mixed disulphide bonds. (d) Use of an unnatural dithiol amino acid, Dtaa,
to moderate the number of possible disulphide patterns. (e) A thiol-con-
taining molecule can react with a disulphide molecule via the thiol-dis-
ulphide exchange reaction. (f ) Disulphide stapling reagents that react
with two Cys residues and form a stable covalent adduct. Selected sta-
pling reagents are shown on the right.
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reactions. For example, proteases are enzymes that catalyse
amide bond hydrolysis, but they can also catalyse amide bond
formation. Indeed, there has been a long history of using pro-
teases to catalyse peptide bond formation.98 However, the
reversible nature of enzyme catalysis can prevent the reaction
from reaching completion. To increase the yield of the desired
ligation product, the reaction equilibrium must be shifted to
favour peptide bond formation.99 This can be achieved by
different tactics, such as the use of thermodynamically less
stable starting materials, alteration of the reaction pH,
inclusion of co-solvents, or addition of additives. All
approaches are theoretically applicable to peptide and protein
substrates prepared either chemically or recombinantly.
3.1. Subtiligase variants
Subtiligase is a double mutant of the serine protease subtilisin
BPN’ from Bacillus amyloliquefaciens.100 It recognises a range
of substrate sequences. Moreover, protein engineering has
afforded variants that have an even wider substrate scope101 or
can function independently of Ca2+.102 The combined
efficiency and broad substrate scope make subtiligase variants
attractive tools for traceless ligation, forming backbone
cyclised peptidyl products (Fig. 6a).100–102 Despite these
appealing features, C-terminal (thio)ester substrates are
required for use by subtiligase variants. Although proteins
with a C-terminal thioester can be produced recombinantly
using an intein-mediated strategy,103 the process is sequence-
dependent and often requires lengthy operational steps that
result in low yields. Consequently, ester and thioester sub-
strates are often made through chemical synthesis, which
limits potential applications.104
3.2. Sortases
Sortases are cysteine transpeptidases found in many bacterial
species, particularly Gram-positive ones. Among those
reported, sortase A from Staphylococcus aureus (SrtA) is the
most widely used for peptide and protein modifications.105
SrtA recognises the amino acid sequence LPXTG, where X is
any amino acid, cleaving the amide bond between Thr and Gly
residues and forming a thioester intermediate at the
C-terminus of Thr, before nucleophilic attack by a peptide with
a N-terminal Gly (Fig. 6b).
With regard to peptide cyclisation, both the length and con-
centration of the peptide have been demonstrated to affect the
preference of SrtA for backbone cyclisation versus oligomerisa-
tion.106 It was reported that substrates of a minimum length of
19 residues (including the LPXTG motif ) are required for cycli-
sation to be favoured over intermolecular reactions (i.e. for-
mation of dimers and trimers in linear or cyclic forms).
Increase of peptide concentration (>1 mM) was unsurprisingly
accompanied with an increase of intermolecular di- and tri-
merisation. SrtA has also been used to cyclise larger recombi-
nant proteins, including various cytokines, green fluorescence
protein (GFP) and ubiquitin C-terminal hydrolase L3.107,108
While SrtA and its variants are valuable tools for peptide
and protein modifications, achieving high ligation yields often
requires the use of excess amounts of nucleophilic peptide due
to the reversible nature of the enzyme. A variety of methods
have been developed to circumvent this problem by the
removal of small glycyl leaving groups using dialysis,109 use of
unnatural starting material to enable quenching of the glycyl
leaving groups,110 or a flow-based system.111 Furthermore,
recent advances in protein engineering have yielded SrtA var-
iants with >100 fold increase in activity,112,113 as well as Ca2+-
independent variants for cellular applications.114
3.3. Asparaginyl endopeptidases
Asparaginyl endopeptidases are cysteine proteases that catalyse
peptide bond cleavage after an Asx (i.e. Asn or Asp) residue.
These enzymes are mostly found in plants, many of which are
capable of mediating transpeptidation, producing naturally
occurring cyclic peptides. Butelase 1 from Clitoria ternatea and
asparaginyl endopeptidase 1 from Oldenlandia affinis (OaAEP1)
are the two most prominent examples which have been uti-
lised for peptide and protein cyclisation.115
Butelase 1 shows a strong preference for the catalysis of
transpeptidation over the hydrolysis of Asx-containing sub-
strates.116 Its efficiency enables low enzyme loading (<0.01
eq.), and its broad sequence promiscuity facilitates transpepti-
dation in a nearly traceless manner. In the butelase 1 reac-
tions, the NHV preferred recognition sequence, is added to the
C-terminal of the substrate (Fig. 6c). Meanwhile, for the
nucleophilic peptide, the N-terminal sequence should start
with either GX or XL (where X is any amino acid, including
D-amino acids).117 Butelase 1 has been employed for backbone
cyclisation of different peptides including the cyclotide kalata
B1, sunflower trypsin inhibitor (SFTI), conotoxin MrIA, insect
antimicrobial peptide thanatin, antimicrobial peptide histatin-
3 and θ-defensin,116,117 as well as proteins including GFP,
interleukin-1 receptor antagonist and somatropin.118
Similar to butelase 1, OaAEP1 exhibits broad sequence
promiscuity. In particular, the variant OaAEP1-C247A, in
which the peptide-binding domain is modified, was reported
Fig. 6 Enzymatic methods for backbone cyclisation (in some cases
recognition sequences may vary): (a) subtiligase, (b) sortase, (c) butelase
1, and (d) OaAEP1.
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to be kinetically superior to that of the wild-type enzyme.119
While NGL is its native recognition sequence (Fig. 6d), the Gly
residue can be replaced with most other amino acids (except
Pro), and the Leu residue can be replaced with other bulky
amino acids (e.g. Phe, Ile, Met, Trp).104 Moreover, OaAEP1 can
be easily produced in E. coli without lengthy activation or puri-
fication steps, unlike many other asparaginyl endopepti-
dases.104 A variety of molecules have been cyclised by
OaAEP1,104,119–121 including an intrinsically disordered
protein, MSP2,121 which butelase 1 failed to cyclise.118
In addition to butelase 1 and OaAEP1, new asparaginyl
endopeptidases are continuously being discovered and
employed for peptide and protein cyclisation, some of these
include HaAEP1,122 MCoAEP2123 and VyPAL1-3.124 These
advances not only provide more ligation tools but also
enhance our understanding of the molecular mechanism of
the enzymes, laying the foundation for engineering variants
with versatile functions. Theoretically, asparaginyl endopepti-
dases can be employed in living systems, such as for the modi-
fication of cell surface proteins, although this has only been
demonstrated with butelase 1.125
3.4. Transglutaminase
The enzymes discussed so far catalyse head-to-tail cyclisation
by amide bond formation between the terminal carboxylic acid
and amino groups. There are also enzymes that facilitate bond
formation between amino acid side chains. Transglutaminases
are a family of enzymes, found in microorganisms, plants and
animals, that catalyse an acyl transfer reaction between the car-
boxyamide group of glutamine residues and various primary
amines (including the ε-amino group of lysine residues), with
NH3 released as a by-product.
126 The resulting crosslinking
amide bond, known as an isopeptide bond, is chemically and
proteolytically stable.127 A calcium-dependent microbial trans-
glutaminase from Streptomyces mobaraensis was used to cyclise
a variety of peptide sequences ranging from 11 to 23 amino
acids.128,129 Broad substrate specificity was observed, although
an Ala and Leu dipeptide sequence was required at the
N-terminal side of the glutamine residue.128 Generally, isopep-
tide bond formation will occur so long as both substrate lysine
and glutamine residues are accessible to the enzyme. However,
the sequence of amino acids flanking the glutamine residue
may also affect the reaction yield.130
Despite having been demonstrated as a useful peptide cycli-
sation tool, with benefits including its tolerance to a range of
temperatures and pH values, irreversible ligation, and com-
mercial availability, there are few examples in the literature of
microbial transglutaminase-catalysed cyclisation due to low
sequence specificity when the polypeptide of interest contains
multiple lysine and glutamine residues.128
3.5. Non-ribosomal peptide synthetases
Many important natural cyclic peptides (and depsipeptides)
are constructed by non-ribosomal peptide synthetases (NPRS).
NRPS are large multifunctional enzymes that assemble one
type of polypeptide without the need for cell ribosomal
machinery and messenger RNAs. Each module of the NRPS is
responsible for the incorporation of a specific amino acid
building block. These modules are further divided into
domains which catalyse a single reaction step.131 At minimum,
a NRPS module is composed of three domains (Fig. 7):
(1) Adenylation (A) domain activates a specific amino acid
by transesterification with ATP to generate the corresponding
aminoacyl-adenylate.
(2) Thiolation (T) domain (also known as the peptidyl
carrier protein) tethers the activated substrate to the enzyme
through the formation of a thioester linkage.
(3) Condensation (C) domain catalyses the formation of a
peptide bond between the activated acyl group and the free
amino group of an amino acid on the neighbouring module.
In this way, the peptide chain grows in the N-to-C-terminal
direction, until it is released by a thioesterase (TE) domain
through either hydrolysis, oligomerisation or cyclisation, cata-
lysed by the active site Ser-His-Asp catalytic triad.132,133
However, the large size (often 100 to 300 kDa) and complex
Fig. 7 Non-ribosomal peptide synthesis by NRPS modules composed
of adenylation (A), thiolation (T) and condensation (C) domains with a
terminal thioesterase (TE) domain.
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multidomain structures of NRPS make their heterologous
expression challenging, and has therefore lead to the develop-
ment of alternative methods of production.134 For example,
cell-free protein synthesis was employed for the in vitro recon-
stitution of the non-ribosomal cyclic peptide valinomycin gene
cluster. As a result, valinomycin was produced in a yield of
∼30 mg L−1, comparable to that of native Streptomyces
organisms.135
In addition, TE domains can also function as isolated
enzymes. For example, cyclic tyrocidine A was generated from
its linear precursor by the TE domain of tyrocidine
synthetase.136,137 Synthetic peptide substrates are activated by
the attachment of N-acetylcysteamine (SNAC) to the
C-terminus. In this way, the natural tethering of the peptide
chain, through the cofactor 4′-phosphopantetheine, is imi-
tated. Furthermore, NRPS can be merged with SPPS for cyclis-
ing peptides immobilised on solid supports.138
The ability of NRPS to incorporate unnatural and D-amino
acids, as well as carry out modifications such as epimerisation,
methylation and reduction, results in large structural diversity
of peptide products. Although reprogramming of these complex
enzymes has so far yielded mixed results,139 the potential for
the manipulation of NRPS remains great, especially with
advances in the understanding of NRPS. For some dedicated
recent reviews on this subject please refer to references.140,141
3.6. Remarks
Any enzyme that catalyses peptide bond formation can be
potentially used for backbone cyclisation. Subtiligase, sortases,
asparaginyl endopeptidases and their variants are some of the
most popular choices due to their ability to generate the
desired cyclic products in high yields. Enzymes, such as trans-
glutaminase, that catalyse bond formation between amino
acid side chain groups can also be employed. However, larger
proteins may contain multiple enzyme recognition sites,
resulting in increased off-target modifications or degradation
of the protein substrate. This is particularly the case for
enzymes that have relaxed substrate specificity (e.g. subtiligase
derivatives, asparaginyl endopeptidases and transglutami-
nase). Moreover, the recombinant expression and purification
of the enzyme, for example butelase 1 or NRPS, can be
laborious.104,142 These considerations should be taken into
account when using enzymatic approaches for cyclisation.
Some of the key features of each enzymatic approach are sum-
marised in Table 2.
4. Using a protein tag for cyclisation
Non-catalytic protein domains can also be used for cyclisation
of peptides and proteins. These protein domains need to be
fused to the polypeptide of interest, commonly achieved by
genetic means. Consequently, these approaches are particu-
larly suitable for production of cyclic peptides and proteins in
living systems, which can be technically challenging by other
methods.
4.1. Inteins
An intein is a protein domain that undergoes self-splicing.143
In this process, the intein excises itself from the protein and
joins its flanking sequences, known as exteins, with a peptide
bond. The splicing process is normally spontaneous, requiring
only the correct folding of the intein to bring the extein
termini into close proximity. It also does not require the pres-
ence of a cofactor or external energy source.
Mechanistically, the splicing begins with N–S or N–O acyl
shift leading to the formation of a (thio)ester intermediate, fol-
lowed by trans(thio)esterification between N- and C-exteins
resulting in a branched intermediate. Next, intein excision pro-
ceeds through asparagine (or sometimes glutamine) cyclisa-
tion before S–N or O–N acyl shift take place to form the
peptide bond between the exteins (Fig. 8a).
Inteins can be used to generate recombinant peptidyl frag-
ments with a C-terminal thioester (Fig. 8b), which is required
in native chemical ligation. This concept, known as expressed
protein ligation (EPL), has greatly expanded the scope of native
chemical ligation and has also been applied to cyclise large
recombinantly produced proteins (e.g. β-lactamase).22
While the majority of inteins exist in a single contiguous
form, such as those employed for EPL, some inteins naturally
exist as two separate polypeptide chains. These split inteins
undergo a trans-splicing mechanism, in which the N- and
C-intein fragments first associate to form the active complex in
the correct conformation before the splicing takes place
(Fig. 8c).143 A prominent example is found in the DnaE gene of
cyanobacterium Nostoc punctiforme PCC73102. This split intein
is known as Npu DnaE. It exhibits fast splicing kinetics (k = 3.7
× 10−2 s−1)144 and good tolerance towards extein sequence vari-
ations,145 compared to another commonly used DnaE split
intein from Synechocystis sp. PCC6803 (Ssp DnaE) which is
more sensitive to variation in the extein sequence around the
splice junction.144,146 By correctly positioning the two frag-
ments of a split intein at the two ends of a peptide, a cyclic
peptide is generated upon intein splicing. This strategy, com-
monly referred to as split-intein circular ligation of peptides
and proteins (SICLOPPS), has been employed for backbone
cyclisation of peptides and proteins in E. coli, yeast and mam-
malian cells.23,147,148
Overall, inteins are useful tools for backbone cyclisation
that can be achieved in a (nearly) traceless manner, whereby
only a single Cys/Ser residue remains at the ligation site after
intein splicing takes place. With increased understanding and
their wide spread occurrence in nature, new inteins have been
engineered with improved properties, although limitations
still remain.149 Most commonly, the introduction of an intein
can lead to protein misfolding. The relatively large size of the
intein can also lead to reduced yields from recombinant
expression.150–154 Lastly, gene expression of the Npu DnaE split
intein has been reported to be toxic to E. coli, an issue that
was circumvented by the incorporation of a degradation tag to
remove any spliced intein fragments or unspliced starting
material.155
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4.2. Protein tags for isopeptide bond formation
Formation of isopeptide bonds between amino acid side
chains can be used to form circular polypeptides structures
that are chemically stable and protease resistant. The CnaB2
domain of the fibronectin binding protein FbaB from
Streptococcus pyogenes was found to contain an isopeptide
bond between a Lys and an Asp residue. When splitting the
CnaB2 domain into a 13-residue SpyTag peptide (containing
the Asp) and a 116-residue SpyCatcher segment (containing
the Lys), the two fragments were found to spontaneously and
efficiently reconstitute in vitro and in vivo with an isopeptide
bond formed between the Asp and Lys residues (Fig. 9a and
b).156 Rapid isopeptide bond formation (k ∼103 M−1 s−1) was
observed under a variety of reaction conditions (4–37 °C, pH
5.0–8.0 with no requirement for specific anions or cations).
The SpyTag/SpyCatcher partners have been used to cyclise
different proteins including β-lactamase, dihydrofolate
reductase, firefly luciferase and L-phenylalanine aldolase, all of
which showed improved stability compared to their linear
forms.24,157,158
Similarly, another isopeptide bond forming pair, known as
SnoopTag (12 residues) and SnoopCatcher (112 residues), was
developed by splitting the D4 Ig-like domain of adhesin RrgA
from Streptococcus pneumonia.159 In this case, the isopeptide
bond formation occurs between Asn and Lys residues and,
importantly, it is orthogonal to the analogous SpyTag/
SpyCatcher reaction. SnoopTag/SnoopCatcher was also
employed to cyclise firefly luciferase.24 It was observed to
confer improved stability to the cyclised product compared to
the linear control, albeit enhancement was not as great as that
observed with the SpyTag/SpyCatcher system.
The spontaneous formation of an isopeptide bond proves
that SpyTag/SpyCatcher and SnoopTag/SnoopCatcher methods
are practical and useful alternatives for protein cyclisation by
genetically fusing the two components to the N- and C-termini
of the target protein. Nevertheless, this approach leaves a large
“scar” with >100 amino acids remaining in the cyclised pro-
ducts after ligation. This has been addressed by the develop-
ment of a catalytic system composed of three parts, SpyTag,
KTag and SpyLigase. To do this the 116-residue SpyCatcher
was split into a 10-residue KTag and a 98-residue SpyLigase
Fig. 8 (a) Mechanism of intein splicing (X = O or S). (b) Cyclisation by expressed protein ligation. (c) Intein-mediated backbone cyclisation.
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(the missing residues were omitted during the restructuring of
the SpyCatcher fragment).160 In this system, shorter peptidyl
fragments SpyTag and KTag, containing the reactive Asp and
Lys residues, respectively, are incorporated into the substrate(s)
of interest and subsequently crosslinked by the addition of
SpyLigase (Fig. 9c). Similarly, SnoopTag/SnoopCatcher was rede-
signed into a 12-residue SnoopTagJr, a 23-residue DogTag and a
104-residue SnoopLigase.161 While the use of SpyLigase or
SnoopLigase significantly reduces the number of amino acid
residues left on the cyclic product, addition of >20 amino acids
residues is still required by these means. Nevertheless, these
approaches are all theoretically applicable in living systems as
demonstrated with SpyTag/SpyCatcher in various examples.162
4.3. Remarks
In summary, protein tag cyclisation is a convenient method for
cyclising recombinantly produced polypeptides, as the long
protein tag sequences can be expressed alongside those of the
peptide/protein of interest. In addition, cyclisation by protein
tag methods generally proceed in a spontaneous and efficient
manner. While intein-mediated cyclisation is considered trace-
less due to the excision of the intein sequence during splicing,
isopeptide bond forming Tag/Catcher partners leave a large
footprint at the ligation site, although it has been shown to
aid protein stabilisation.
5. Considerations for cyclisation
Various methods for polypeptide cyclisation have been dis-
cussed along with their strengths and limitations which are
summarised in Table 3. Unfortunately, no method is ideally
suited for the cyclisation of all peptides and proteins. This
section will focus on several key factors that should be con-
sidered when choosing a cyclisation approach.
5.1. Distance between connecting residues
For protein substrates, it is important to consider the locations
of the connecting residues. If located too far apart, the pro-
tein’s complex folded structure may be disrupted as a result of
strain, leading to loss of activity. It was found that in approxi-
mately 2000 representative proteins, 31% have their termini
within 20 Å and 11% within 15 Å.163 Therefore, a large number
of proteins could theoretically be amenable to head-to-tail
cyclisation, as well as side chain-to-side chain cyclisation,
assuming it is the side chain residues at, or close to the
termini, that are to be linked together. Nevertheless, whichever
mode of cyclisation is chosen, existing structural information
can be used to select the most appropriate positions to take
part in cyclisation. In cases where termini are located too dis-
tally for a suitable direct connection, linker sequences can be
introduced to extend the termini, or bridging reagents of
appropriate length can be used for connecting side
chains.164,165 Interestingly, when cyclising granulocyte-colony
stimulating factor using a split intein-mediated ligation
approach, it was shown that the structure of the connector
could be optimised to promote either enhanced stability or
efficiency of cyclisation.148 When a longer connecter was
employed, the increase in thermal stability was found to be
greater (∼11 °C increase compared to a shorter linker).
However, splicing efficiency was reduced, with unspliced start-
ing material remaining. Although distortion caused by cyclisa-
tion is disadvantageous for improved stability and activity, it
can be exploited. For example, cyclic luciferase was employed
for real-time sensing of caspase-3 activity in living
mammals.166 Cyclisation by split intein led to distortion of the
luciferase structure and hence loss of bioluminescence activity.
If N- and C-termini were linked by the caspase-3 recognition
sequence (DEVD), the cyclised luciferase, in the presence of
functional caspase-3, would be restored to its original active
form and bioluminescence observed.
On the other hand, for peptide substrates without a specific
three-dimensional conformation, factors such as ring size (i.e.
length of linear precursor) and peptide sequence are known to
affect cyclisation efficiency, as well as the reagents and con-
ditions employed for cyclisation.167 Before cyclisation can take
place, the reactive termini of the linear precursor must come
into close proximity with one another. As such, cyclisation is
favoured over intermolecular reaction. Various strategies have
been developed to facilitate ring closure by pre-organisation of
the linear peptide into a conformation predisposed to promote
cyclisation.28 Generally, these involve the use of templates and
modifications to the peptide sequence to increase flexibility or
the introduction of turn-inducers (e.g. proline).168
5.2. Means to produce the polypeptide of interest
Another factor to consider is the method by which the poly-
peptide of interest is to be produced and purified. A chain of
Fig. 9 Cyclisation by a protein tag. (a) Isopeptide bond formation
through a catcher and a tag. (b) Mechanism of isopeptide bond for-
mation in SpyCatcher/SpyTag. (c) Catalytic version of SpyCatcher/
SpyTag.
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amino acids can be produced either chemically or recombi-
nantly using cellular machinery. Solid-phase peptide synthesis
is arguably the most common chemical means employed to
generate peptides, whereby a solid support is used for the step-
wise assembly of the peptide chain. After cleavage from the
solid support, peptides are usually purified using reverse-
phase HPLC. Larger polypeptides can also be synthesised
chemically as smaller fragments which are later joined
together for example using native chemical ligation.34,35
However, it is often preferable to prepare larger proteins by
recombinant approaches using cellular machinery. This first
requires molecular cloning for the introduction of the DNA
molecule, containing the gene of the target protein, into cells.
Once transformed, the recombinant DNA is transcribed into
mRNA before translation into the target protein.169
Recombinantly produced polypeptides often require a number
of chromatographic steps to achieve the desired level of purity.
Most commonly these include affinity, ion-exchange and/or
size exclusion chromatographies. It should be noted that
affinity chromatography usually requires the incorporation of
an affinity tag sequence (e.g. His-Tag used for immobilised
metal affinity chromatography) into the polypeptide of interest,
hence, an additional cleavage step to remove the tag may be
required. Below, for each category of cyclisation approach, the
relevance of chemical and recombinant preparation will be
discussed.
Chemical cyclisation approaches often require non-native
functionalities (see Table 1) or take place under non-physio-
logical conditions (e.g. in organic solvent). As chemical syn-
thesis is often favoured for the incorporation of non-native
functionalities into specific positions within the polypeptide
chain, it is perhaps the more convenient preparation method
when using chemical cyclisation approaches. While it is also
possible to introduce non-native functionalities by recombi-
nant means such as genetic code expansion, there are more
limitations in terms of amino acid substrates that can be
introduced (see section 2.4). In addition, peptides can be
synthesised in fully protected forms as required for some
chemical ligation methods such as direct amide bond for-
mation. On-resin cyclisation can also be carried out, which
can be advantageous to solution phase approaches which
often require high dilutions to minimise intermolecular
reactions which generate dimer and oligomer side products.
High dilution can also lead to long reaction times which in
turn lead to epimerisation at the ligation site.170 Using the
on-resin approach, the antibacterial peptides polymyxin B2,
E2 and a derivative were cyclised. The peptides were
anchored to the resin by the amine group of a lysine side
chain.171 Upon removal of C- and N-terminal protecting
groups, the peptides cyclised efficiently in good yields and
exhibited antibacterial activities comparable to that of
natural polymyxins. Alternatively, peptides can be anchored
to the resin by the C-terminal carboxyl group through the
use of safety-catch linkers.172,173 For example, the cyclisation
of brachystemin A was carried out successfully using this
approach.174
Preparation of enzymes is often essential when they are
used as catalysts for cyclisation. However, this process can be
time-consuming and labour-intensive, unless the enzyme is
commercially available (e.g. sortase). Generally, enzymatic
cyclisation can be applied to material produced by any means,
although care should be taken with larger proteins which may
contain multiple recognition sequences and thus result in off-
target modifications causing degradation of the linear starting
material and/or cyclised product.121
Protein tag cyclisation approaches such as intein and iso-
peptide bond forming Tag/Catcher partners are generally com-
posed of sequences of ∼100 amino acid residues. It is therefore
convenient to recombinantly express these long protein tag
sequences alongside that of the polypeptide sequence of inter-
est, as opposed to chemical synthesis followed by ligation to
generate the required sequence. Moreover, it should be noted
that while peptides are usually produced in a low yield when
using recombinant production methods,175 the addition of the
large flanking protein tag sequences required for cyclisation
can facilitate their preparation by cellular machinery. When
using intein-mediated cyclisation, these long sequences are
excised during the cyclisation process and so do not remain in
the product.155
5.3. Application-related factors
The type of cyclisation approach chosen can also depend on
the eventual application of cyclised peptide or protein. Below,
a few examples of application-related consideration will be
discussed.
5.3.1. Stability. Cyclisation is a useful technique for
enhancing the stability of peptides and proteins and can
therefore expand the scope of their application, for example
as biocatalysts or as therapeutics. While there are numerous
examples of proteins whose thermal stability has been
increased as a result of cyclisation,17 the largest improvement
towards heat treatment is often observed when cyclisation is
carried out using isopeptide bond forming peptide/protein
partners, in particular SpyTag/SpyCatcher.157 For example,
SpyTag/SpyCatcher was demonstrated to stabilise PhyC
phytase from heat induced aggregation at 100 °C and enabled
the cyclised enzyme to be purified from cell lysate just by
heating.176 Upon investigation using differential scanning
calorimetry, it was found that isopeptide bond forming
domains are likely conferring extra thermal resilience, on top
of that achieved through cyclisation, by facilitating protein
refolding after heat treatment.176
With regard to proteolytic stability, it may be useful to con-
sider the mode of cyclisation, i.e. head-to-tail versus side chain
cyclisation. Exopeptidases are enzymes that hydrolyse the
terminal amide bonds of polypeptide chains. Thus, side chain
cyclisation approaches which leave the termini free, for
example disulphide bond formation, may leave the polypep-
tide susceptible to proteolytic degradation. For this reason, a
head-to-tail cyclisation approach should result in improved re-
sistance to proteolysis. For example β-lactamase, cyclised using
an intein-mediated ligation approach, was shown to be resis-
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tance to treatment by carboxypeptidase Y, which hydrolyses
C-terminal amide bonds.22 On a related note, proteolytic treat-
ment can be used to test if cyclisation of a polypeptide has
taken place, whereby digestion would only be observed if the
linear form is present.23
5.3.2. Library generation. Cyclic peptides are promising
therapeutic candidates. In the process of identifying potential
drug molecules through high-throughput screening tech-
niques, a diverse library of cyclic peptide sequences needs to
be generated. Some examples of popular methods employed
for creating libraries of cyclic peptides include phage display,
SICLOPPS and mRNA display, which will briefly be discussed
below in the context of strengths and limitations of the cyclisa-
tion approach on the resulting cyclic peptide library.177
In phage display, bacteriophages that have been genetically
modified to display unique peptides on the surface of their
coat proteins, are screened for desired activity (e.g. selection by
binding to a target molecule).178 By sequencing the phage
DNA, the identity of the target-binding peptide can be deter-
mined. Phage display is a well-established and effective tech-
nique, and cyclic peptides can be generated by intramolecular
disulphide bond formation between cysteine residues located
either side of a randomised amino acid sequence (i.e. CXnC,
where Xn is any number of any amino acids).
179–181 However,
Table 2 Enzymatic and protein tag approaches for cyclisation. All approaches are theoretically applicable to peptide and protein substrates pre-








Subtiligase variants Backbone Peptide ester/thioester + XXa 0 X
Sortases Backbone LPXTG + GG 6 (LPXTGG) ✓
Asparaginyl endopeptidase – butelase 1 Backbone N/D-HV + G/L-X 3 (NXX) ✓




Side chain K + Q 0 or 2 (Lys and
Gln)
✓
Protein tag – intein Backbone Split N- and C-inteins 0 or 1 (Cys) ✓
Protein tag – SpyTag/SpyCatcher Side chain Formation of an isopeptide bond
between SpyTag/SpyCatcher
129 ✓













a Subtiligase variants have very broad substrate scope but the identity of substrate residues in positions P1–P4 and P1′–P2′ influences the ligation
efficiency. Generally, hydrophobic residues are preferred. b OaAEP1 can recognise a wide range of substrates, although its native substrates have
the sequence NGL + GL.










Direct coupling Often required in the starting
material
Backbone Peptides X X
Native chemical ligation Incorporation of thioester
motif
Backbone Peptides, proteins ✓ Xb
Ser/Thr ligation Required Backbone Peptides X X
CyClick Required Backbone Peptides X X
Traceless Staudinger ligation Required in the starting
materials
Backbone Peptides X X
KAHA (type I and II) Required Backbone Peptides X X
TAMM Required Side chain Peptides, proteins ✓ ✓
Cu-catalysed azide–alkyne
cycloaddition (CuAAC)
Required Side chain Peptides, proteins ✓ X
Strain promoted azide–alkyne
cycloaddition (SPAAC)
Required Side chain Peptides, proteins X ✓
Cysteine disulphides Not needed Side chain Peptides, proteins ✓ ✓
Orthogonal disulphide pairing Required Side chain Peptides X X
Disulphide stapling Present in the products Side chain Peptides, proteins ✓ X
aUnnatural functionality refers to presence of any moiety that cannot be produced from 20 canonical amino acids. b See section 4.1 for the
recombinant extension to native chemical ligation (i.e. expressed protein ligation) which can be used in living systems.
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Table 3 Summary of peptide/protein cyclisation techniques
Cyclisation approach Advantages Factors to be considered
Chemical Disulphide bond formation • Cysteine residues easily introduced chemically
or recombinantly (easily applied to smaller
peptides and larger proteins)
• Not stable under reducing conditions (i.e.
intracellular environment); could be addressed
through the use of disulphide stapling reagents
• Disulphide formation occurs readily under
mild aqueous conditions
• Correct disulphide bond formation can be
difficult to control and may lead to a mixture of
products (addressed by orthogonal disulphide
pairing but requires unnatural functionalities)
Direct cyclisation • Activation of the terminal carboxylic acid
group allows reaction to proceed under mild
conditions
• Nucleophilic and carboxylate amino acid side
chains require protection to prevent side
reactions
• Limited to synthetic peptides
CyClick • Efficient, chemo- and stereoselective • Requires an unnatural functionality in the
starting material (C-terminal aldehyde);
introduction can be achieved synthetically or
through chemical modification (e.g. sodium
periodate oxidation of Ser/Thr)
• Can be performed at high concentrations
without the formation of side products from
intermolecular reactions
Native chemical ligation • Reaction proceeds in aqueous conditions at
neutral pH
• A C-terminal thioester is required which is
introduced synthetically (addressed by
expressed protein ligation)
• Presence of chaotropic agents and reducing
agents are tolerated and in some cases
preferable
• Some NCL extensions involve the use of an
unnatural thiol- or selenol-containing
N-terminal amino acid in place of cysteine
• Regio- and chemo-selective reaction
• A number of extensions have been developed
for broader application (e.g. desulphurisation)
Staudinger ligation • Traceless cyclisation • Requires unnatural functionalities
• Chemoselective towards the azide (protecting
groups not required)
• Phosphinothiols only have limited solubility
in aqueous solution
• Glycine residues required at the ligation site
α-Ketoacid-hydroxylamine
ligation (Type II KAHA)
• Cyclises both longer and shorter polypeptides • Requires unnatural functionalities in the
starting material
• O-Substituted hydroxylamine is water stable • A homoserine residue is formed at the ligation
site (although oxazetidine can be used in place
of oxaproline to form a serine residue)
• Chemoselective • Reaction is relatively slow
• Forms a native peptide bond
Cu-Catalysed azide–alkyne
cycloaddition
• Efficient and regioselective • Requires unnatural functionalities (azide and
alkyne)
• Requires only mild conditions and can be
carried out in water
• Cu(I) catalyst must be generated in situ from
Cu(II) by the use of excess reducing agent and
Cu-stabilising ligands




• Circumvents the requirement for a copper
catalyst
• Lacks regiospecificity (forms a mixture of 1,4-
disubstituted products)
• Rapid reaction under physiological conditions • Cyclooctyne reagents are relatively costly
Enzyme Subtiligase (and variants) • Very broad substrate scope • Promiscuity may result in off-target
modificationsx
• Effectively traceless • Effectively traceless
Sortase A • Well-studied and understood enzyme • Ligation is reversible as the LPXTG
recognition sequence remains in the product
• Mutants have been developed for improved
activity
• Relatively low catalytic efficiency
• Commercially available • Ca2+ dependence, limited use in vivo
Asparaginyl endopeptidase • Exhibit high catalytic efficiency and requires a
low enzyme-to-substrate ratio
• Short recognition sequence may lead to off-
target modifications in larger proteins
• Relatively broad substrate scope and short
recognition sequence
• Recognition sequence remains in the product
leading to reversibility of the reaction
• Nearly traceless cyclisation (only Asx remains)
Microbial transglutaminase (S.
mobaraensis)
• Calcium independent (in contrast to
mammalian transglutaminases)
• Low substrate specificity
• Resulting isopeptide bond is chemically and
proteolytically stable
• Preference for glutamine residues is unclear
• Tolerant to a broad range of reaction
conditions
Review Organic & Biomolecular Chemistry























































































cyclic peptides produced by this method are susceptible to
reduction (i.e. linearisation) under reducing conditions.
Alternatively, cyclic peptides can be generated using bioortho-
gonal reactions. For example, TAMM condensation was used to
generate cyclic peptide library on bacteriophages, providing
potent cyclic peptide binders to Bcl-2, Mdm2 and Keap1.60
Using SICLOPPS, cyclic peptide libraries can be prepared
intracellularly.23 Here, a peptide library is created by randomis-
ation of the extein sequence encoded by degenerate oligonu-
cleotides.182 Upon excision of the split intein sequences, the
termini of the extein sequence are ligated and the cyclic
peptide generated via the formation of a native peptide bond.
Cyclic peptide libraries have been generated using a variety of
host cells, including E. coli, yeast and mammalian
cells.147,183,184 This intracellular generation of cyclic peptides
is advantageous, as it enables the use of cell-based screening
against intracellular protein targets, as opposed to in vitro
screening which does not always accurately reflect activity and
function in vivo. Furthermore, it has been demonstrated that
cyclic peptide libraries bearing non-canonical amino acids can
be generated using this approach.185 However, like phage
display peptide libraries, the maximum number of library
members is limited by transformation efficiency of the host
cells.182 In addition, the use of split inteins leads to certain
extein sequence requirements and sometimes toxicity towards
E. coli (see section 4.1).
A third strategy for cyclic peptide library generation is
mRNA display. In this approach, the linear peptide is attached
to its encoding mRNA sequence through a puromycin linker at
the C-terminus.186,187 As such, highly efficient side chain-to-
side chain or side chain-to-N-terminus cyclisation approaches
are required.188 Disulphide bond formation between two
cysteine residues is the most straightforward of these strat-
egies. However, the use of bridging reagents and the incorpor-
ation of non-native amino acids189,190 can afford a wide range
of possible cyclisation patterns, especially in the presence of
multiple reactive residues.191 While non-specific cyclisation
can make hit deconvolution difficult, increased library diver-
sity and therefore investigation of a broader range of cyclic
peptide scaffolds is advantageous.192 Recently, using an
approach based on native chemical ligation, head-to-tail cycli-
sation of peptides compatible with mRNA display was
reported, further broadening structural variety of mRNA
display peptide libraries.193
5.3.3. Size of footprint at ligation site. Broadly speaking, it
is often preferable to have as little evidence of ligation remain-
ing in the cyclised polypeptide product as possible (i.e. for
cyclisation to be traceless). However, in most cases some form
of footprint remains at the ligation site, whether it is a particu-
lar amino acid residue such as cysteine in NCL or Asx from the
asparaginyl endopeptidase recognition sequence, the for-
mation of a non-native group for example a 1,4-disubstituted
triazole resulting from CuAAC, or a large protein tag sequence
from SpyTag/SpyCatcher cyclisation. It should be noted, these
scars are not always disadvantageous, although care should be
taken that they will not interfere deleteriously with the
intended function of the cyclised polypeptide.
6. Conclusion and perspectives
This review provides an overview of the approaches currently
available for polypeptide cyclisation. Ideally, a cyclisation
approach that is specific, traceless and applicable to both
chemically and recombinantly prepared materials is desired.
There is yet to be such an ideal method, and each reported
method has its own strengths and limitations (Table 3).
Generally, the choice of the most suitable approach largely
Table 3 (Contd.)




• Able to incorporate unnatural and D-amino
acids, and can carry out modifications such as
epimerisation, methylation and reduction
• So far reprogramming has yielded mixed
results
• TE domains can function as isolated enzymes • Large size makes heterologous expression
challenging
• A deeper understanding of these complex





ligation and split intein
mediated splicing)
• Overcomes size limitation of native chemical
ligation
• Can result in low protein yields after
recombinant expression
• Almost traceless cyclisation (only Cys/Ser
remains)
• Can lead to misfolding of the protein of
interest




• Wide range of reaction conditions • Leaves a large scar at the ligation site
(addressed by the development of Spy- and
SnoopLigase)
• High yielding and fast
• Does not require separate expression and
purification
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depends on the sequence, how the material is produced and
the desired application. While the production of chemically
synthesised polypeptides is generally more laborious for
longer sequences, they can be cyclised by a broader range of
techniques. On the other hand, the preparation of polypep-
tides by recombinant approaches is technically simpler, but
contains more restrictions (stereochemistry, incorporation of
unnatural functionalities and polypeptide lengths). It is also
noteworthy that many cyclisation approaches are theoretically
orthogonal to each other and can be used to generate multiple
cyclic structures simultaneously. Although this is a less
explored direction, it may be an interesting area for future
research with the potential to further expand the scope of
application of cyclic polypeptides.
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